Effect of nitric oxide-donor, linsidomine chlorhydrate, in treatment of human erectile dysfunction caused by venous leakage

Wegner, H; Knispel, Helmut H.

doi:10.1016/0090-4295(93)90371-g

Cited by 24 publications

(15 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12,54 In a small comparative trial conducted by the author in 40 patients, the ef®cacy-rates (partial or full rigidity) after 1 mg SIN-1 were 35% compared to 82.5% after alprostadil 20 mg. 12 Due to these signi®cantly lower ef®cacy-rates with admittedly low side effect rates, the compound was not pursued further and did not enter a full clinical trial program toward market development.…”

Section: Current Perspectives On Intracavernosal Pharmacotherapy H Porstmentioning

confidence: 99%

Current perspectives on intracavernosal pharmacotherapy for erectile dysfunction

Porst¹

2000

Int J Impot Res

View full text Add to dashboard Cite

Thirty percent of males af¯icted with erectile dysfunction (ED) do not respond to oral drugs, another 15% reveal contraindications to currently available therapy, and a subset of patients actually prefer injection therapy due to its predictable short time-to-onset of erection and reliable rigidity compared to oral drugs. This paper provides both a historical and current perspective on intracavernosal therapy and reviews the popular injectable therapeutic agents that are currently used for the treatment of ED. Emphasis is placed on the ef®cacy, mechanism of action and side effect pro®les of approved and experimental injectable pharmacotherapy for ED.

show abstract

Section: Current Perspectives On Intracavernosal Pharmacotherapy H Porstmentioning

confidence: 99%

Current perspectives on intracavernosal pharmacotherapy for erectile dysfunction

Porst¹

2000

Int J Impot Res

View full text Add to dashboard Cite

show abstract

“…It has been established that NO is the neurotransmitter responsible for cavernous smooth muscle relaxation [4]. This finding as well as the availability of a direct NO donor, SIN-1, has prompted different research groups to apply the in vitro findings [10][11][12] to the clinical situation. The drug used, SIN-1 (3-morpholinosydnonimin), is an antianginal drug; the dosage recommended by its man ufacturer for its initial purpose, coronary angiography, is 0.4-1 mg [ 13], The plasma half-life of SIN-1 is about 1 h [14].…”

Section: Discussionmentioning

confidence: 99%

“…SIN-1 has been shown to relax human cavernous smooth muscle in vitro [15]. When injected intracavernosally it has been shown to induce tumescence as well as erection [10][11][12], PGEi is the drug of choice for intracavernous injection for erectile dysfunction. Of the other drugs available, PGEi causes the lowest number of complications and has results as good as its predecessor, papaverine [3], Its effect is mediated by cavernous receptors [19], It is presently considered the 'gold standard' of vasoactive drugs in the treatment of erectile dysfunction.…”

Section: Discussionmentioning

confidence: 99%

Prostaglandin E<sub>1</sub> versus Linsidomine Chlorhydrate in Erectile Dysfunction

Wegner

Knispel²,

Klän³

et al. 1994

Urol Int

Self Cite

View full text Add to dashboard Cite

Recent experimental work has demonstrated that nitric oxide (NO) is the neurotransmitter responsible for cavernous smooth muscle relaxation. Different studies on the performance of the direct NO donor linsidomine chlorhydrate (SIN-1) in patients with erectile dysfunction have had conflicting results. We performed a single-blind cross-over trial in 20 patients with erectile dysfunction of mixed etiology comparing prostaglandin E₁ (PGE₁) to SIN-1 at two different dosages (1 and 2 mg, respectively) in order to determine the effectiveness of SIN-1. PGE₁ always achieved the best response, SIN-1 performed statistically significantly poorer irrespective of the dosage used. There were only a few side effects with no significant difference. SIN-1 is not a useful alternative to PGEi in the treatment of erectile dysfunction.

show abstract

“…Intracavernous linsidomine (SIN-1), on the other hand, has also been shown to be significantly inferior than intracavernous prostaglandin E 1 to induce penile erections [13, 14]. Sodium nitroprusside has been shown to be effective in inducing erections in rats, dogs and monkeys [15, 16, 17].…”

Section: Discussionmentioning

confidence: 99%

Prospective Comparative Study with Intracavernous Sodium Nitroprusside and Prostaglandin E<sub>1</sub> in Patients with Erectile Dysfunction

Martínez‐Piñeiro

Cortés²,

Cuervo³

et al. 1998

European Urology

View full text Add to dashboard Cite

Effect of nitric oxide-donor, linsidomine chlorhydrate, in treatment of human erectile dysfunction caused by venous leakage

Cited by 24 publications

References 13 publications

Current perspectives on intracavernosal pharmacotherapy for erectile dysfunction

Current perspectives on intracavernosal pharmacotherapy for erectile dysfunction

Prostaglandin E<sub>1</sub> versus Linsidomine Chlorhydrate in Erectile Dysfunction

Prospective Comparative Study with Intracavernous Sodium Nitroprusside and Prostaglandin E<sub>1</sub> in Patients with Erectile Dysfunction

Contact Info

Product

Resources

About